PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) is set to present preclinical data from its innovative cancer cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting 2024. The event, a significant gathering of cancer researchers and clinicians, will take place from April 5-10, 2024, in San Diego, CA.
Century Therapeutics’ presentations will focus on its Induced Pluripotent Stem Cell (iPSC)-derived cell therapy platform. The company’s research encompasses iPSC reprogramming and differentiation, gene editing, protein engineering, and computational biology. In addition, Century will share new preclinical data on its Allo-Evasion™ edits, which could further bolster its multi-dosing strategy.
The company will present six posters during the conference. Highlights include:
- “The Discovery of A Novel CD19xCD22 Dual-Targeting CAR For The Development Of An iPSC-Derived Cell Therapy,” presenting a potential new avenue for the development of cell therapies targeting CD19 and CD22, two proteins commonly found on the surface of certain types of cancer cells.
- “Engineered Expression Of HLA-E And HLA-G Protects iPSC-Derived Cells from Killing By Primary NK Cells,” discussing how certain engineered proteins can protect iPSC-derived cells from destruction by the body’s natural killer (NK) cells.
- “Screening iPSC Lines for Optimal Characteristics of Differentiation into Immune Effector Cells for Clinical Programs,” detailing the methods used to identify iPSC lines best suited for differentiation into immune effector cells, which play a crucial role in the body’s response to cancer.
- “Discovery of a Novel Nectin4 iPSC-derived Cell Therapy for the Treatment of Solid Tumors,” showcasing a new iPSC-derived cell therapy targeting Nectin4, a protein often found on the surface of solid tumors.
- “Discovery Of Inhibitory CAR Target DSG1 For Damping NECTIN4 On-Target Off-Tumor Toxicity in iPSC-Derived CAR-T Cell Therapy,” presenting a novel way to reduce unintended off-target effects in CAR-T cell therapy targeting Nectin4.
- “CXCR4 Transgene Improves In Vivo Migration and Efficacy of Engineered iPSC-Derived Natural Killer Cells,” discussing how the addition of the CXCR4 transgene could enhance the effectiveness of engineered iPSC-derived natural killer cells in combating cancer.
The company’s participation in the AACR Annual Meeting 2024 signals its commitment to pioneering research and development in the field of cancer cell therapy. With its emphasis on iPSC-derived therapies, Century Therapeutics is at the forefront of efforts to develop more effective cancer treatments.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.